Expired
Lead Plaintiff Deadline
Jan 16, 2026
Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Skye Bioscience, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
In order to be eligible to join the SKYE class action lawsuit, you must have incurred a loss on shares of Skye Bioscience, Inc. purchased during the class period listed above.
If you suffered a loss in Skye Bioscience, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until January 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
